Literature DB >> 3882281

Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A.

M G Jones, G Harris.   

Abstract

Oral administration of cyclosporin A (Cy A), an immunosuppressive agent, prolonged the life span of female NZB/NZW (F1) hybrid mice (NZB/W). The most prominent feature of this study was the reduction of glomerular proliferation, proteinurea, and delay of renal failure. Protection from renal damage, in treated mice, occurred despite similar degrees of perivascular cellular infiltration in the kidney and other organs, and glomerular deposition of immunoglobulin and complement. Treatment did not influence the hypergammaglobulinaemia, high levels of circulating immune complexes and later development of autoimmune haemolytic anaemia typically associated with this murine disease. The levels of antibodies to double stranded DNA (dsDNA), an important disease marker, and the response to sheep red blood cells were reduced in the Cy A treated mice, in contrast with the untreated mice. Levels of rheumatoid factors were increased in Cy A treated mice, when compared with untreated mice, and this could play a role in prolongation of life associated with protection from glomerular damage, although it was considered that inhibitory effects on T cell function were a more likely mechanism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882281      PMCID: PMC1577167     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone.

Authors:  M C Gelfand; A D Steinberg
Journal:  Arthritis Rheum       Date:  1972 May-Jun

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies.

Authors:  K Yonemasu; R M Stroud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

Review 4.  Disordered immunologic regulation and autoimmunity.

Authors:  N Talal
Journal:  Transplant Rev       Date:  1976

5.  Skin transplantation in mice and dogs. Effect of cyclosporin A and dihydrocyclosporin C.

Authors:  J F Borel; J Meszaros
Journal:  Transplantation       Date:  1980-02       Impact factor: 4.939

6.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

7.  Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice.

Authors:  M W Steward; F C Hay
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

8.  Influence of diet on survival of mice.

Authors:  G Fernandes; E J Yunis; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

9.  Cyclosporin A inhibits acute serum sickness nephritis in rabbits.

Authors:  G H Neild; K Ivory; M Hiramatsu; D G Williams
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

10.  Reversal of nzb/nzw disease with total lymphoid irradiation.

Authors:  B L Kotzin; S Strober
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more
  11 in total

1.  Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis.

Authors:  H C Gunn; B Ryffel
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

2.  The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice.

Authors:  R V Bundick; R P Eady
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Cyclophosphamide and 15(S)-15 methyl PGE1 correct the T/B lymphocyte ratios of NZB/NZW mice.

Authors:  D Girard; R M Aloisi; M L Bliven; A C Cunningham; I G Otterness
Journal:  Agents Actions       Date:  1990-03

5.  Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

Authors:  A Tarkowski; K Gunnarsson; T Stålhandske
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

6.  Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.

Authors:  M Dougados; H Awada; B Amor
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

7.  Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies.

Authors:  H C Gunn
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

8.  Suppression of autoimmune disease in NZB/W F1 mice by treatment with the novel immunomodulator BTS 63155.

Authors:  P Appleby; G Telford; G B Naylor
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Inhibition of in vitro NZB antibody responses by cyclosporine.

Authors:  D S Pisetsky
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

Review 10.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.